Given the capability of the nanobody 1A5 to inhibit the proliferation of EGFR‐TKI‐resistant NSCLC cells, we next examined the effect of 1A5 on the growth of NSCLC tumors. Here, EGFR is linked to non-small cell lung carcinoma.